| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.8 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0063 | 0.8 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.8 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.8 |